Tuesday, March 22, 2022 9:29:06 PM
I think you have it right senti, neoantigens are not found on normal tissue and are tumor-specific. They can be highly immunogenic as they are recognized by the immune system as non-self, so they make good cancer targets. You have probably even heard jondoeuk gushing about development on various neoantigen-based treatments. :) But it sounds like you may be struggling with the question: How could targeting neoantigens be better than DCVax which targets all the antigens?
Short answer is, I don’t think it is a better approach than DCVax. But T-cell treatments have been all the rage since the CAR-T treatments Kymriah and Yescarta were approved in 2017, and there is a general belief that T-cell therapy is more effective than a dendritic cell therapy, which hasn’t been proven in clinical trials, or commercially approved (yet). (well other than Provenge and exwannabe’s favorite - Apceden)
So with this in mind, the BATON system was designed in 2016 to make a T-cell therapy. It uses the dendritic cells to load the T-cells with multiple neoantigens (rather than a single antigen like CAR-T’s) that are specific to each person’s tumor, and then cultures those activated T-cells. It’s a more natural, faster, and far less expensive method of manufacturing a T-cell treatment than engineering the T-cells, and it’s also potentially more effective and durable since it targets multiple antigens to prevent escape.
I think this system is really brilliant, and it could add value to Northwest Bio at some point down the road. Northwest Bio could develop a T-cell therapy, which could be used as a mono-therapy, or it could be combined with DCVax as a dendritic-cell vaccine shot and a T-cell infusion, or it could be combined with checkpoint inhibitors, etc., or the manufacturing system could be licensed.
Short answer is, I don’t think it is a better approach than DCVax. But T-cell treatments have been all the rage since the CAR-T treatments Kymriah and Yescarta were approved in 2017, and there is a general belief that T-cell therapy is more effective than a dendritic cell therapy, which hasn’t been proven in clinical trials, or commercially approved (yet). (well other than Provenge and exwannabe’s favorite - Apceden)
So with this in mind, the BATON system was designed in 2016 to make a T-cell therapy. It uses the dendritic cells to load the T-cells with multiple neoantigens (rather than a single antigen like CAR-T’s) that are specific to each person’s tumor, and then cultures those activated T-cells. It’s a more natural, faster, and far less expensive method of manufacturing a T-cell treatment than engineering the T-cells, and it’s also potentially more effective and durable since it targets multiple antigens to prevent escape.
I think this system is really brilliant, and it could add value to Northwest Bio at some point down the road. Northwest Bio could develop a T-cell therapy, which could be used as a mono-therapy, or it could be combined with DCVax as a dendritic-cell vaccine shot and a T-cell infusion, or it could be combined with checkpoint inhibitors, etc., or the manufacturing system could be licensed.
Recent NWBO News
- Form 8-K - Current report • Edgar (US Regulatory) • 04/07/2026 04:30:50 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/31/2026 09:04:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/15/2026 10:06:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/02/2026 10:14:59 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/28/2025 09:43:27 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 11/26/2025 05:15:34 AM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/25/2025 10:23:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2025 09:26:03 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 11/19/2025 09:15:48 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:44:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/31/2025 04:29:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2025 08:40:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/24/2025 04:28:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/14/2025 06:22:26 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2025 09:00:38 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 07/01/2025 09:04:38 PM
